Chronic Gastritis Clinical Trial
Official title:
Evaluation of Immunohistochemical Expression of Heparanase in Helicobacter Pylori-Associated Chronic Gastritis
Treatment of H.pylori may not be achieved in many patients with chronic gastritis. Termination of the inflammatory respose produced by h.pylori may be useful in management of difficult cases. Heparanase is a pro-inflammatory mediator. Blocking of heparanase may relief the symptoms of chronic gastritis.
Chronic gastritis (CG) is a very common disease. The incidence of CG is not accurately known. However, it is clear that the incidence of CG is increasing by advancing age. CG is divided into two main types; type A or immune and type B or non-immune gastritis. Both types of CG share the same histological features. However, type A is less common, usually affects the gastric fundus in a diffuse manner and separates the antrum. on the contrary; type B or non-immune CG, which is by far more common, inevitably develops in the antrum and progresses proximally. H. pylori-induced CG usually requires antibiotic therapy to eradicate the causative organism and subsequently terminate the inflammatory response and the symptoms of gastritis. However, eradication of H. pylori is difficult to be achieved in many patients. Previous studies established that there is a vicious circle between H. pylori-infected gastric epithelial cells and the gastric mucosal inflammatory cells. Heparanase (HPSE) is a mammalian ᵦ-endoglucoronidase. HPSE plays a critical role in multiple inflammatory processes by degrading and remodeling heparan sulfate polysaccharide chains in the extracellular matrix (ECM). This leads to release of multiple cytokines and chemokines which are located in the ECM. HPSE is a drug target, three inhibitors of this enzyme have been tested in early stage clinical trials. Many studies reported that the expression of HPSE is up-regulated in a variety of inflammatory conditions as ulcerative colitis, acute pancreatitis, acute vasculitis and sepsis. The aim of this work is to evaluate the role of heparanase (HPSE) in chronic gastritis (CG) by correlating the expression of HPSE to different histological features of CG as presence of H. pylori, chronic inflammatory infiltrate, gastric atrophy, intestinal metaplasia and neutrophil infiltrate (activity), to detect new treatment modalities in CG. ;
Status | Clinical Trial | Phase | |
---|---|---|---|
Completed |
NCT04066530 -
A Study to Evaluate the Efficacy and Safety of AD-203
|
Phase 3 | |
Recruiting |
NCT05048069 -
Post-Marketing Surveillance of Safety and Effectiveness of Mucosta®SR Tab.
|
||
Completed |
NCT01817556 -
A Study to Evaluate the Efficacy and of Stillen Tab. and to Demonstrate the Non-inferiority of Stillen Tab.
|
Phase 4 | |
Recruiting |
NCT01813812 -
A Study to Evaluate the Efficacy and Safety of DA-6034 and to Demonstrate the Non-inferiority of DA-6034
|
Phase 3 | |
Completed |
NCT00996788 -
Anti Free Radical & Anti Inflammatory Effect & Safety of Rebamipide in Chronic Gastritis
|
Phase 3 | |
Completed |
NCT04341454 -
Study to Evaluate the Efficacy and Safety of DWP14012 in Patients With Acute or Chronic Gastritis
|
Phase 3 | |
Enrolling by invitation |
NCT05021029 -
A Study of Pre-Malignant Gastric Conditions
|
||
Completed |
NCT04697186 -
Helicobacter Pylori Eradication With Berberine Plus Amoxicillin Triple Therapy Versus Bismuth-containing Quadruple Therapy
|
Phase 4 | |
Recruiting |
NCT00455806 -
Esomeprazole, Moxifloxacin and Amoxicilin for Rescue Therapy of Helicobacter Pylori Infection
|
Phase 3 | |
Recruiting |
NCT05666531 -
Research on Innovative Diagnosis and Treatment System of Syndrome Differentiation of Zang-fu Viscera and Effectiveness Evaluation Based on Inter-Arm Blood Pressure Measured Simultaneously
|
||
Completed |
NCT03847753 -
Exploring the Comorbidity Between Mental Disorders and General Medical Conditions
|
||
Completed |
NCT04189705 -
A Study to Evaluate the Efficacy and Safety of MCT-SR in Patients With Gastritis
|
Phase 3 | |
Completed |
NCT05014334 -
Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication
|
Phase 4 | |
Completed |
NCT02356679 -
Efficacy and Safety of Eupasidin-s Tab.(EUPASIDIN-S) in Gastritis Patients
|
Phase 4 | |
Completed |
NCT02219529 -
Magnetic-controlled Capsule Endoscopy vs. Gastroscopy for Detection of Gastric Diseases
|
Phase 3 | |
Completed |
NCT03609892 -
Helicobacter Rescue Therapy With Berberine Plus Amoxicillin Quadruple Therapy Versus Tetracycline Plus Furazolidone Quadruple Therapy
|
Phase 4 | |
Unknown status |
NCT02282670 -
A Study to Evaluate the Efficacy and Safety of DA-5204
|
Phase 3 | |
Completed |
NCT01119768 -
Esomeprazole Treatment Co-diagnosed Non Erosive Reflux Disease (NERD) and Chronic Gastritis Patients
|
Phase 4 | |
Completed |
NCT02658864 -
Pharmacokinetic Properties and Effect of Food on Pharmacokinetic Properties of the Oral Lafutidine Tablets
|
Phase 1 |